An observational study in COVID19, Influenza Vaccination and ACE Inhibitors, sponsored by Consorci Sanitari de Terrassa. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Consorci Sanitari de Terrassa · Observational
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.
Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.
The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied.
If patients that previously received the influenza vaccine or treated with ACEI, ARB, antihistamines or amantadine showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the treatment of infection.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →Consorci Sanitari de Terrassa is the lead sponsor of 41 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All hospital admissions in the Hospital of Terrassa from March 1, 2020 were innitially included.
Population of reference: the population assigned to the Terrassa Health Consortium population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed.
Drug: Antihistamine · Drug: Amantadine · Drug: ACEI · Drug: ARB · Other: Influenza vaccine and COVID
COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with antihistamines. No intervention is performed.
Drug: Antihistamine
COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with amantadine. No intervention is performed.
Drug: Amantadine
No intervention is performed. We propose an observational study.
Also known as: Antihistamines for COVID
No intervention is performed. We propose an observational study
Also known as: Amantadine for COVID
No intervention is performed. We propose an observational study.
Also known as: ACEI and COVID
No intervention is performed. We propose an observational study.
Also known as: ARB and COVID
No intervention is performed. We propose an observational study.
hospital output
exitus vs hospital output
Time frame: from March 1, 2020.
hospital stay
length of the hospital stay
Time frame: From March 1, 2020.
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorci Sanitari de Terrassa